Impact of Therapeutic Intervention on Quality of Life in Patients With Ulcerative Colitis

Launched by GRUPO ESPANOL DE TRABAJO EN ENFERMEDAD DE CROHN Y COLITIS ULCEROSA · Feb 28, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how different treatment approaches impact the quality of life for patients with Ulcerative Colitis (UC), a type of Inflammatory Bowel Disease (IBD). The researchers are particularly interested in how changes in medication—either increasing or decreasing the dosage or switching to a new treatment—affect patients who have shown signs of healing in their colon. They will also be looking at a specific marker in stool, called fecal calprotectin, to help understand inflammation levels.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of UC. They should also have had a colonoscopy that shows mild or no inflammation while they are feeling well. Participants can expect to contribute to important research that may help improve treatment strategies for UC patients in the future. The study is currently recruiting participants, so if you or someone you know meets these criteria and is interested, it could be a great opportunity to make a difference.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • UC diagnosed.
• • Age ≥ 18.
• • Signed and dated informed consent form.
• • Have undergone a Mayo 0 or 1 endoscopic score colonoscopy while in clinical remission.
• Exclusion Criteria:
• • Incomplete colonoscopy.
• • Previous bowel resection.
• • Ostomy patient.
• • Active infection.
• • Pregnancy.
• • Lack of patient's informed consent.